Supplements for Parkinson's Disease: What the Trials Actually Show
If you are searching for a supplement that slows or prevents Parkinson's disease, the honest answer is that none has been proven to do that. Large trials have tested coenzyme Q10, vitamin E, creatine, and other promising molecules for neuroprotection, and vitamin D mainly for motor symptoms. None of the neuroprotection candidates met the bar. Supplements can still matter in narrower ways. They can correct a real deficiency, support nutrition, and address specific nutritional needs alongside prescribed care. They are not a substitute for the treatment your neurologist prescribes. This guide grades the evidence one supplement at a time, explains the levodopa interactions that matter more than any pill, and shows what to test before you spend money.
In This Guide
What neuroprotection means and why no supplement has met the bar
Neuroprotection means protecting brain cells from the damage that drives Parkinson's disease. In practice, researchers look for a treatment that slows progression on a clinical scale, delays the need for levodopa, or changes a biomarker in a meaningful way. That is a high bar.
It requires large trials, long follow-up, and a product that actually reaches the brain at a useful dose.
No supplement has cleared that bar. The Parkinson's Foundation says there is not enough scientific evidence to recommend supplements for Parkinson's disease [32]. The Michael J. Fox Foundation is more direct: it says no supplement is known to slow or prevent the disease, and that supplements are adjuncts, not replacements for proven treatment [33].
A 2024 meta-analysis of 24 studies found that dietary supplements did not significantly change total UPDRS, UPDRS III, or six-minute walk distance. Diet patterns did [28].
Why the gap? Parkinson's disease involves several pathways at once: protein clumping, mitochondrial stress, inflammation, and neurotransmitter loss. A single nutrient rarely moves all of them.
Many trials also used a dose that was too low, a form that absorbed poorly, or a sample too small to detect a modest effect. Some promising early results came from open-label studies with no placebo group, which is the weakest kind of evidence.
It helps to separate four different outcomes:
- Disease modification: whether progression slows. No supplement has shown this.
- Motor symptoms: tremor, rigidity, slowness, walking. A few supplements show small, uncertain effects.
- Non-motor symptoms: constipation, sleep, mood, fatigue. Evidence is early and strain-specific.
- Lab markers: vitamin levels, homocysteine, inflammatory markers. Supplements can move these numbers.
The key takeaway: a supplement can improve a lab marker or a symptom score without changing the disease. Grade each claim by the outcome it actually measured.
The supplements with the strongest evidence, graded one by one
Each entry below reports what the best available trial or review found, the dose and sample size where the source gives them, and a grade. The grades are about evidence, not popularity. A failed trial is still useful information.
CoQ10
CoQ10 looked promising in a phase II trial, so researchers ran a much larger phase III study called QE3. It enrolled 600 people with early Parkinson's disease and compared 1,200 mg/day and 2,400 mg/day of CoQ10 with placebo for 16 months. The trial was stopped for futility.
Adjusted UPDRS worsening was 6.9 points on placebo, 7.5 on the lower dose, and 8.0 on the higher dose. There was no benefit [1].
The Michael J. Fox Foundation lists high-dose CoQ10 as not beneficial and does not recommend it [33]. Grade: failed for disease modification. Do not buy it for neuroprotection.
Vitamin E
The DATATOP trial tested alpha-tocopherol, a form of vitamin E, in people with early Parkinson's disease. It produced no benefit [2]. That result has held up.
Vitamin E is important for general nutrition, and food sources are fine. High-dose supplements are a different question, and the trial evidence does not support them for Parkinson's progression.
Grade: failed for disease modification.
Creatine
Creatine was tested as a possible way to support energy metabolism in brain cells. A Cochrane review included two randomized trials with 194 patients and found no clear effect [3]. An updated meta-analysis of five trials with 1,339 participants found no significant difference in total, mental, activities of daily living, or motor UPDRS scores [4].
The results are consistent, and the meta-analysis is large. Grade: failed for disease modification and for motor symptoms.
Vitamin D
Vitamin D is the clearest example of "test, do not guess." A meta-analysis of eight randomized trials with 646 patients found no benefit on UPDRS III motor scores. The weighted mean difference was -0.56 points, with a 95% confidence interval of -2.34 to 1.23. Six-minute walk distance did improve by 24.85 meters, with a confidence interval of 6.54 to 43.16 [5].
That walk result is interesting but modest.
A separate trial gave 60 patients 2,000 IU/day for 12 weeks. It corrected deficiency but produced no significant motor, cognitive, or quality-of-life benefit [6].
Grade: correct a documented deficiency, but do not expect it to improve motor symptoms.
Low vitamin D is common and worth treating for bone and general health. That is a different goal from neuroprotection.
Thiamine and benfotiamine
High-dose thiamine has open-label support, not large randomized support. One open-label study gave 50 patients 100 mg of thiamine intramuscularly twice weekly. UPDRS total fell from 38.55 to 18.16 at three months, and UPDRS III fell from 22.01 to 9.92.
There was no placebo group [7]. A case series of three newly diagnosed patients reported motor UPDRS improvements ranging from 31.3% to 77.3% with parenteral high-dose thiamine [8].
Open-label results can reflect expectation, natural fluctuation, or regression to the mean. The study used an injection, so the result does not tell us what an oral benfotiamine capsule would do. The Michael J. Fox Foundation cautions against high-dose B1 unless a deficiency is documented [33].
Grade: promising but unproven. Not a substitute for a prescribed regimen, and not something to start at high dose on your own.
NAC and glutathione
N-acetylcysteine (NAC) is a building block for glutathione, an antioxidant. A 2026 systematic review covered nine studies with 196 participants. NAC was associated with improved motor and non-motor symptoms and with higher glutathione ratios, higher cerebrospinal fluid glutathione, and greater dopamine transporter binding.
Intranasal glutathione raised brain glutathione modestly but did not improve symptoms [9].
The authors describe the evidence as preliminary. The studies were small, and routes of delivery differ a lot. Intravenous glutathione is not a proven treatment, and the Michael J. Fox Foundation cautions that IV glutathione carries risk and is not recommended [33].
Grade: preliminary. Do not treat a review of 196 people as proof.
Citicoline
Citicoline has been studied as an add-on to levodopa. A systematic review found seven studies: two crossover trials, three randomized controlled trials, and two open prospective studies. Reports described improvements in rigidity, akinesia, tremor, handwriting, speech, and cognition, plus a reduction in levodopa dose of up to 50% in some studies [10].
The review also calls the evidence heterogeneous and low quality. A possible levodopa-sparing effect is interesting, but it is also a reason not to experiment alone. If citicoline changes how much levodopa you need, that is a neurologist decision.
Grade: low-quality signal, not established care.
Probiotics
Constipation is a common non-motor symptom of Parkinson's disease [26], and researchers have studied probiotics as a possible support [11]. A pilot study of Lactobacillus plantarum PS128 gave 25 patients 60 billion CFU nightly for 12 weeks. UPDRS motor scores improved in both OFF and ON states, ON/OFF duration and PDQ-39 quality of life improved, and there was no non-motor effect.
The study was open-label, with no placebo group [11].
A separate randomized trial of 46 patients combined probiotics with vitamin D for 12 weeks. It reduced IL-1beta, IFN-gamma, IL-6, and MDA, raised IL-10 and total antioxidant capacity, and reduced disease severity, anxiety, and gastrointestinal problems [12]. That is a lot of moving parts in a small trial.
Grade: early and strain-specific. Probiotics may support digestive comfort, but the Parkinson's-specific evidence is not settled.
Omega-3 fatty acids
Omega-3 evidence is mixed and comes mostly from small trials. One randomized trial gave 60 patients 1,000 mg of flaxseed omega-3 plus 400 IU of vitamin E for 12 weeks. UPDRS changed by -3.3 points with the supplement and +4.4 with placebo, a statistically significant difference in a small sample [14].
A second trial tested a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins in 40 patients with early Parkinson's disease over 30 months. It reported significantly delayed UPDRS progression compared with placebo [15]. Both trials are small, and neither has settled the question.
Grade: mixed, with small positive signals that need replication.
Two more candidates deserve a mention because they are popular. Caffeine was tested in the Cafe-PD trial with 121 patients taking 200 mg twice daily for 6 to 18 months. It produced no motor benefit, a slight increase in dyskinesia, and worse cognitive testing [23].
An earlier, smaller trial had shown equivocal sleepiness benefit and improved motor scores over a short period [24]. Mannitol was tested in 14 active and 8 placebo participants at up to 18 g/day for 36 weeks [34]. It was safe, gastrointestinal symptoms limited the dose in 6 of 14 people, and there was no efficacy difference [13].
Grade for both: not recommended based on current evidence.
Mucuna pruriens: a supplement that acts like a drug
Mucuna pruriens is sold as a natural supplement. It is not a vitamin or a mineral. Its seeds contain levodopa, the same active ingredient in many prescription Parkinson's medicines [16][17].
That single fact should reset how you think about it. You are not choosing between a drug and a gentle herb. You are choosing between a regulated medicine with a known dose and an unregulated plant product with a variable dose.
Trials have compared Mucuna with commercial levodopa. Randomized and open-label studies show symptomatic benefit that is comparable to commercial levodopa [16]. That sounds positive, but symptom relief is not the same as disease modification.
The problem is consistency and safety. Levodopa content varies from seed to seed, from batch to batch, and from product to product [16]. A label that lists a standardized percentage does not guarantee what is in the capsule [16].
The risks are the same class as prescription levodopa, plus the risk of uncontrolled dosing. They include dyskinesia, dopamine dysregulation syndrome, psychiatric complications, and toxicity from improper preparation [16]. Dopamine dysregulation syndrome is a compulsive pattern of overuse, and it can happen with any levodopa source [16].
Poorly prepared products add another layer of risk.
The key takeaway: Mucuna is a levodopa delivery system, not a benign supplement. Use it only under neurologist supervision, at a known dose, with the same monitoring as prescription levodopa. Never self-adjust it, and never stop or change prescribed medication to try it.
The levodopa interaction rules that matter more than any supplement
If you take carbidopa/levodopa, the timing of food, iron, and other pills can change how much levodopa you absorb and how you feel [27][31]. These interactions can matter more than any supplement on this page. These are not instructions to change your treatment. They are questions to bring to your neurologist, because every medication change is a neurologist decision.
Protein timing
A high-protein meal can reduce levodopa bioavailability and blunt the response [25][26]. Some people notice a clear pattern: their medication works well until a protein-heavy meal, then fades. Others notice nothing.
The practical question is whether your dose timing should move relative to protein, not whether you should cut protein out of your diet. Protein matters for muscle, immune function, and weight maintenance. Ask your neurologist before you change meal timing or dose timing.
Iron and ferrous sulfate
Ferrous sulfate is a common iron supplement, and it can bind levodopa in the gut. In a study of eight healthy volunteers, 325 mg of ferrous sulfate taken with 250 mg of levodopa reduced peak levodopa by 55% and the area under the curve by 51% [31]. That is a large effect in a small, short study, but the mechanism is plausible and the warning is standard.
Do not stop iron on your own if your clinician has told you that you need it. Instead, ask whether the iron can be separated from levodopa by a few hours, and whether your iron dose is still appropriate.
Timing is the question. Self-discontinuation is not the answer.
Vitamin C, fiber, and coffee
Vitamin C, fiber, and coffee may improve levodopa absorption [25]. The evidence is not strong enough to prescribe a routine, and none of these should be used to replace a dose. Coffee is a good example of why you need to separate questions.
Coffee may affect absorption, but caffeine itself did not improve motor symptoms in a large trial [23]. Those are different claims.
Ask whether your fiber supplement, vitamin C, or coffee routine should be timed around your medication. Do not change your medication schedule to fit a supplement.
Vitamin B6, B12, folate, and homocysteine
This is the interaction cluster most people miss. Carbidopa/levodopa can lower vitamin B6 over time. In one study of 24 patients treated for three years or more, 19 had low plasma B6, and 8 of those 19 had symptoms of deficiency.
Higher cumulative levodopa/carbidopa doses correlated with lower B6 [18].
But more B6 is not automatically better. High-dose B6 can cause a sensory axonal neuropathy, and neurotoxicity typically appears at levels above 100 nmol/L [19][20]. Both deficiency and excess are risk factors for peripheral neuropathy.
That is why testing beats guessing.
Homocysteine adds another layer. Levodopa is metabolized by COMT, an enzyme that uses vitamin B12, B6, and folate as cofactors [21][22]. Levodopa can raise homocysteine, and B vitamins can lower it.
Whether everyone on levodopa should take routine B vitamins, or whether monitoring B vitamin levels and homocysteine is enough, is still debated [21]. A reasonable plan is to measure B12, folate, B6, and homocysteine, then let your neurologist interpret the results.
The key takeaway: B6 can be too low or too high. Test it, do not guess, and do not stack high-dose B vitamins without a reason.
What to test before you buy anything
Testing turns a guess into a plan. These are the labs most relevant to the supplements in this guide. Your neurologist or primary care clinician can order them, and your insurance may cover them.
- 25-hydroxy vitamin D: shows whether you have a deficiency worth correcting. Deficiency is common and worth treating for bone health. The motor evidence in Parkinson's disease is negative [5][6].
- Vitamin B12: relevant to nerve health and homocysteine metabolism. Low B12 can cause neuropathy and cognitive symptoms [22].
- Folate: works with B12 in homocysteine metabolism [21].
- Vitamin B6: can be low on long-term carbidopa/levodopa, and can be too high with supplementation [18][19][20].
- Homocysteine: a functional marker that can rise with levodopa use [21].
- Iron studies, including ferritin: only if iron deficiency is suspected or iron is being considered. Iron interacts with levodopa [31].
A few rules make testing useful:
- Test before you start a supplement, not after.
- Test one change at a time so you know what moved the number.
- Bring the actual results to your neurologist, not just "my B12 was low."
- Do not chase a number into a high dose. More is not better for B6 or vitamin D.
The key takeaway: test first, correct documented deficiencies, and skip supplements that are only guessing at a number you have not measured.
What to ask your neurologist
Bring a written list and a bag of every supplement you take, including dose and brand. The goal is not to get permission for a favorite product. The goal is to catch interactions before they cause a problem.
Questions worth asking:
- Do any of my supplements interact with my carbidopa/levodopa dose?
- Should I test vitamin D, B12, folate, B6, or homocysteine?
- If my B6 is low, how much should I take, and for how long?
- If my homocysteine is high, do I need B vitamins or just monitoring?
- Should I time protein, iron, vitamin C, fiber, or coffee around my medication?
- Is Mucuna pruriens ever appropriate for me, and if so, at what dose and with what monitoring?
- Are any of my supplements enzyme inducers that could affect my other medicines?
- What symptoms should make me call you rather than adjust anything myself?
The key takeaway: ask about interactions and timing, not just "is this okay?" A good answer names the dose, the timing, and the monitoring plan.
What we recommend, and what we do not
The principle is simple: test first, correct deficiencies, and do not buy neuroprotection.
Choose third-party tested products. A supplement that fills a measured gap is useful. A supplement that promises to protect brain cells without evidence is a subscription to hope.
What we recommend:
- Correct a documented vitamin D deficiency, with the dose and follow-up your clinician sets [5][6].
- Correct low B12 or folate, especially if homocysteine is high [21][22].
- Test B6 before supplementing it, and avoid high-dose B6 without a reason [18][19][20].
- Choose products from manufacturers that publish third-party testing and clear labels.
- Change one thing at a time so you can tell what helped and what did not.
- Keep a current medication and supplement list for every appointment.
What we do not recommend:
- High-dose CoQ10 for neuroprotection after the QE3 result [1][33].
- High-dose vitamin E for disease modification after DATATOP [2].
- Creatine for Parkinson's progression or motor symptoms [3][4].
- Mucuna pruriens without neurologist supervision [16][17].
- Intravenous glutathione except in a supervised clinical trial [33].
- High-dose thiamine or benfotiamine without a documented deficiency [33].
- St John's wort. It is a potent enzyme inducer and interacts with many prescription drugs, including MAO-B inhibitors and antidepressants [29][30][32].
- Stacking many supplements at once, which makes interactions and side effects impossible to trace.
St John's wort deserves its own warning. It activates PXR and induces CYP3A4 and P-glycoprotein, which changes levels of digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin, and oral contraceptives [29][30].
The Parkinson's Foundation specifically warns that it may interact with MAO-B inhibitors [32]. If you are on an MAO-B inhibitor or an antidepressant, do not add it.
The key takeaway: spend on testing and quality, not on neuroprotection claims. The product cards below are chosen to match documented needs, not to imply disease benefit.
XYMOGEN, Methyl Protect 120 Capsules
A methylated B-vitamin formula with folate, B12, B6, B2, and trimethylglycine, for the homocysteine and B-vitamin lab work this guide describes. Use it only when testing has shown a gap and your clinician has set the dose.
$74.99
Researched Nutritionals, CoreBiotic® 60 Capsules
A spore-based probiotic chosen for the digestive support discussed above, one of the non-motor issues people can raise with their care team.
$41.98
Integrative Therapeutics, Vitamin C with Quercetin 180 Veg Capsules
A vitamin C and quercetin formula for antioxidant support. The vitamin C timing question raised in the levodopa section is one to settle with your neurologist before you add it.
$42.50
DaVinci Labs, Vitamin D3 5000 IU 120 Capsules
A vitamin D3 option for a deficiency confirmed by a 25-hydroxy vitamin D test, with the dose and follow-up your clinician sets.
$32.82
Frequently asked questions
Can any supplement slow Parkinson's disease?
No. The Michael J. Fox Foundation says no supplement is known to slow or prevent Parkinson's disease, and the Parkinson's Foundation says there is not enough scientific evidence to recommend supplements for Parkinson's [32][33]. A meta-analysis of 24 studies found no significant effect of dietary supplements on total UPDRS, UPDRS III, or six-minute walk distance [28].
Supplements can correct deficiencies and support general health, but they do not replace prescribed treatment.
Is CoQ10 worth taking for Parkinson's?
Not for neuroprotection. The QE3 trial tested 1,200 and 2,400 mg/day in 600 people for 16 months and found no benefit, with the trial stopped for futility [1].
The Michael J. Fox Foundation also lists high-dose CoQ10 as not beneficial [33].
Does vitamin B1 help Parkinson's?
The evidence is open-label only. A 50-patient study reported large UPDRS improvements with 100 mg intramuscular thiamine twice weekly, but there was no placebo group [7]. A three-patient case series also reported improvement [8].
High-dose B1 should not be started without a documented deficiency and neurologist guidance [33].
Is Mucuna pruriens safe?
It contains levodopa, and its potency varies by seed and product [16]. Unsupervised use carries risks of dyskinesia, dopamine dysregulation syndrome, psychiatric complications, and toxicity from improper preparation. It should be used only under neurologist supervision, at a known dose, with the same monitoring as prescription levodopa.
Can I take supplements with carbidopa/levodopa?
Some can interact. Ferrous sulfate can lower levodopa absorption [31], high-protein meals can reduce the response [25][26], long-term levodopa can lower B6 [18], and St John's wort can interact with MAO-B inhibitors and many other drugs [29][30][32]. Bring your full supplement list to your neurologist before adding anything.
Does protein affect levodopa?
Yes, a high-protein meal can reduce levodopa bioavailability and blunt the response in some people [25][26]. That does not mean you should cut protein. It means meal and dose timing is worth discussing with your neurologist.
Do not change your medication schedule on your own.
Should I take vitamin B6 if I have Parkinson's?
Only if testing shows you need it. Long-term carbidopa/levodopa can lower B6 [18], but high-dose B6 can cause sensory neuropathy, with toxicity typically above 100 nmol/L [19][20]. Test plasma B6 and let your neurologist set the dose.
What should I test before buying supplements?
Ask about 25-hydroxy vitamin D, B12, folate, B6, and homocysteine. Add iron studies if iron deficiency is suspected [5][18][21][22][31]. Test before starting, change one thing at a time, and bring the actual numbers to your appointment.
References
- Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. doi:10.1001/jamaneurol.2014.131. PMID 24664227. https://pubmed.ncbi.nlm.nih.gov/24664227/
- Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol. 1998;44(3 Suppl 1):S160-S166. PMID 9749589. https://pubmed.ncbi.nlm.nih.gov/9749589/
- Xiao Y, Luo M, Luo H, Wang J. Creatine for Parkinson's disease. Cochrane Database Syst Rev. 2014;2014(6):CD009646. doi:10.1002/14651858.CD009646.pub2. PMID 24934384. https://pubmed.ncbi.nlm.nih.gov/24934384/
- Mo JJ, Liu LY, Peng WB, Rao J, Liu Z, Cui LL. The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials. BMC Neurol. 2017;17(1):105. doi:10.1186/s12883-017-0885-3. PMID 28577542. https://pubmed.ncbi.nlm.nih.gov/28577542/
- Xu J, Li J, Sun YJ, Quan W, Qin YD, Song J, Chen JJ. Effect of vitamin D supplementation on motor symptoms in Parkinson's disease: a meta-analysis of randomized controlled trials. Front Nutr. 2025;12:1500875. doi:10.3389/fnut.2025.1500875. PMID 40551732. https://pubmed.ncbi.nlm.nih.gov/40551732/
- Anamnart C, Kitjarak R. Effect of vitamin D supplementation on clinical outcomes of patients with Parkinson disease: a randomized controlled study. Medicine (Baltimore). 2026;105(30):e49931. doi:10.1097/MD.0000000000049931. PMID 42499083. https://pubmed.ncbi.nlm.nih.gov/42499083/
- Costantini A, Pala MI, Grossi E, Mondonico S, Cardelli LE, Jenner C, Proietti S, Colangeli M, et al. Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study. J Altern Complement Med. 2015;21(12):740-747. doi:10.1089/acm.2014.0353. PMID 26505466. https://pubmed.ncbi.nlm.nih.gov/26505466/
- Costantini A, Pala MI, Compagnoni L, Colangeli M. High-dose thiamine as initial treatment for Parkinson's disease. BMJ Case Rep. 2013;2013:bcr2013009289. doi:10.1136/bcr-2013-009289. PMID 23986125. https://pubmed.ncbi.nlm.nih.gov/23986125/
- Mohammed I, Nankya Y, Hong UT, Kan A, Abdelhafid AM, Latunde-Dada GO. The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes. Amino Acids. 2026;58(1). doi:10.1007/s00726-026-03513-5. PMID 41874704. https://pubmed.ncbi.nlm.nih.gov/41874704/
- Que DS, Jamora RDG. Citicoline as adjuvant therapy in Parkinson's disease: a systematic review. Clin Ther. 2021;43(1):e19-e31. doi:10.1016/j.clinthera.2020.11.009. PMID 33279231. https://pubmed.ncbi.nlm.nih.gov/33279231/
- Lu CS, Chang HC, Weng YH, Chen CC, Kuo YS, Tsai YC. The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson's disease: a pilot study. Front Nutr. 2021;8:650053. doi:10.3389/fnut.2021.650053. PMID 34277679. https://pubmed.ncbi.nlm.nih.gov/34277679/
- Zali A, Hajyani S, Salari M, Tajabadi-Ebrahimi M, Mortazavian AM, Pakpour B. Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson's disease: a randomized controlled clinical trial. Psychopharmacology (Berl). 2024;241(9):1905-1914. doi:10.1007/s00213-024-06606-9. PMID 38805039. https://pubmed.ncbi.nlm.nih.gov/38805039/
- Linetsky E, Abd Elhadi S, Bauer M, Gallant A, Namnah M, Weiss S, Segal D, Sharon R, et al. Safety and tolerability, dose-escalating, double-blind trial of oral mannitol in Parkinson's disease. Front Neurol. 2021;12:716126. doi:10.3389/fneur.2021.716126. PMID 35046880. https://pubmed.ncbi.nlm.nih.gov/35046880/
- Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, Aarabi MH, Kouchaki E, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017;108:183-189. doi:10.1016/j.neuint.2017.03.014. PMID 28342967. https://pubmed.ncbi.nlm.nih.gov/28342967/
- Pantzaris M, Loukaides G, Paraskevis D, Kostaki EG, Patrikios I. Neuroaspis PLP10, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg. 2021;210:106954. doi:10.1016/j.clineuro.2021.106954. PMID 34607196. https://pubmed.ncbi.nlm.nih.gov/34607196/
- Cilia R, Katzenschlager R. "To bean or not to bean": therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens. J Parkinsons Dis. 2026;16(4):788-794. doi:10.1177/1877718X261442075. PMID 42053204. https://pubmed.ncbi.nlm.nih.gov/42053204/
- Rai SN, Chaturvedi VK, Singh P, Singh BK, Singh MP. Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective. 3 Biotech. 2020;10(12):522. doi:10.1007/s13205-020-02532-7. PMID 33194526. https://pubmed.ncbi.nlm.nih.gov/33194526/
- Rojo-Sebastian A, Gonzalez-Robles C, Garcia de Yebenes J. Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa/carbidopa. Clin Neuropharmacol. 2020;43(5):151-157. doi:10.1097/WNF.0000000000000408. PMID 32947426. https://pubmed.ncbi.nlm.nih.gov/32947426/
- Muhamad R, Akrivaki A, Papagiannopoulou G, Zavridis P, Zis P. The role of vitamin B6 in peripheral neuropathy: a systematic review. Nutrients. 2023;15(13):2823. doi:10.3390/nu15132823. PMID 37447150. https://pubmed.ncbi.nlm.nih.gov/37447150/
- Reddy P. Preventing vitamin B6-related neurotoxicity. Am J Ther. 2021;29(6):e637-e643. doi:10.1097/MJT.0000000000001460. PMID 36608063. https://pubmed.ncbi.nlm.nih.gov/36608063/
- Ahlskog JE. Levodopa, homocysteine and Parkinson's disease: what's the problem? Parkinsonism Relat Disord. 2023;109:105357. doi:10.1016/j.parkreldis.2023.105357. PMID 36922273. https://pubmed.ncbi.nlm.nih.gov/36922273/
- Rekik A, Santoro C, Poplawska-Domaszewicz K, Qamar MA, Batzu L, Landolfo S, Rota S, Falup-Pecurariu C, et al. Parkinson's disease and vitamins: a focus on vitamin B12. J Neural Transm (Vienna). 2024;131(12):1495-1509. doi:10.1007/s00702-024-02769-z. PMID 38602571. https://pubmed.ncbi.nlm.nih.gov/38602571/
- Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, et al. Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial. Neurology. 2017;89(17):1795-1803. doi:10.1212/WNL.0000000000004568. PMID 28954882. https://pubmed.ncbi.nlm.nih.gov/28954882/
- Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651-658. doi:10.1212/WNL.0b013e318263570d. PMID 22855866. https://pubmed.ncbi.nlm.nih.gov/22855866/
- Boelens Keun JT, Arnoldussen IA, Vriend C, van de Rest O. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson's disease: a systematic review. Adv Nutr. 2021;12(6):2265-2287. doi:10.1093/advances/nmab060. PMID 34113965. https://pubmed.ncbi.nlm.nih.gov/34113965/
- Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HC, Aureli F, Metta V, Bhidayasiri R, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. Eur J Neurol. 2023;30(5):1465-1480. doi:10.1111/ene.15734. PMID 36757008. https://pubmed.ncbi.nlm.nih.gov/36757008/
- Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(Suppl 2):S253-S261. doi:10.1007/s00415-010-5728-8. PMID 21080186. https://pubmed.ncbi.nlm.nih.gov/21080186/
- Wu L, Chu L, Pang Y, Huo J, Cao H, Tian Q, Gao Q. Effects of dietary supplements, foods, and dietary patterns in Parkinson's disease: meta-analysis and systematic review of randomized and crossover studies. Eur J Clin Nutr. 2024;78(5):365-375. doi:10.1038/s41430-024-01411-1. PMID 38378765. https://pubmed.ncbi.nlm.nih.gov/38378765/
- Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE. Clinical relevance of St. John's wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212-1226. doi:10.1111/bph.14936. PMID 31742659. https://pubmed.ncbi.nlm.nih.gov/31742659/
- Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement-drug interactions. Am Fam Physician. 2017;96(2):101-107. PMID 28762712. https://pubmed.ncbi.nlm.nih.gov/28762712/
- Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther. 1989;45(3):220-225. doi:10.1038/clpt.1989.21. PMID 2920496. https://pubmed.ncbi.nlm.nih.gov/2920496/
- Parkinson's Foundation. Over the counter and complementary therapies. https://www.parkinson.org/living-with-parkinsons/treatment/over-the-counter-complementary-therapies
- Michael J. Fox Foundation. Six common questions about supplements and Parkinson's. https://www.michaeljfox.org/news/six-common-questions-about-supplements-and-parkinsons
- American Parkinson Disease Association. Supplements and herbal remedies for Parkinson's. February 6, 2024. https://www.apdaparkinson.org/article/supplements-for-parkinsons-disease/
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
